Progress of ALK gene inhibitors in the treatment of brain metastases from nonsmall cell lung cancer

doi:10.3760/cma.j.issn.1673-422X.2017.06.018

Abstract

Abstract: Anaplastic lymphoma kinase (ALK) rearrangement is one of the most potent carcinogenic genes in nonsmall cell lung cancer (NSCLC). The firstgeneration ALK inhibitor such as crizotinib is superior to chemotherapy for NSCLC patients with ALK rearrangement. At the same time, more and more studies have reported ALK inhibitors in brain metastases of NSCLC patients with intracranial efficiency. However, despite the initial clinical data of firstgeneration ALK inhibitors in the treatment of ALKpositive NSCLC with brain metastases, different degrees of recurrence of tumors after acquired resistance have posed new challenges for followup treatment of cancer patients. A new generation of ALK inhibitors, such as alectinib, ceritinib, AP26113 and PF06463922 have emerged to solve this problem.

Key words: Carcinoma, nonsmallcell lung, Neoplasm metastasis, Anaplastic lymphoma kinase fusion gene inhibitors

Sun Wenyu, Yan Pengfei, Yuan Yingli, Ma Kewei. Progress of ALK gene inhibitors in the treatment of brain metastases from nonsmall cell lung cancer[J]. Journal of International Oncology, 2017, 44(6): 472-.

References

［1］ Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4ALK fusion gene in nonsmallcell lung cancer［J］. Nature, 2007, 448(7153): 561-566. DOI: 10.1038/nature05945. ［2］ Gainor JF, Varghese AM, Ou SH, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with nonsmall cell lung cancer［J］. Clin Cancer Res, 2013, 19(15): 4273-4281. DOI: 10.1158/10780432.CCR130318. ［3］ Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosisspecific tool to estimate survival for patients with brain metastases［J］. J Clin Oncol, 2012, 30(4): 419-425. DOI: 10.1200/JCO.2011.38.0527. ［4］ Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in nonsmallcell lung cancer［J］. N Engl J Med, 2010, 363(18): 1693-1703. DOI: 10.1056/NEJMoa1006448. ［5］ Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALKpositive nonsmallcell lung cancer: updated results from a phase 1 study［J］. Lancet Oncol, 2012, 13(10): 1011-1019. DOI: 10.1016/S14702045(12)703443. ［6］ Loong HH, Mok K, Leung LK, et al. Crizotinib in the management of advancedstage nonsmallcell lung cancer［J］. Future Oncol, 2015, 11(5): 735-745. DOI: 10.2217/fon.14.314. ［7］ Solomon BJ, Mok T, Kim DW, et al. Firstline crizotinib versus chemotherapy in ALKpositive lung cancer［J］. N Engl J Med, 2014, 371(23): 2167-2177. DOI: 10.1056/NEJMoa1408440. ［8］ Costa DB, Shaw AT, Ou SH, et al. Clinical experience with crizotinib in patients with advanced ALKrearranged nonsmallcell lung cancer and brain metastases［J］. J Clin Oncol, 2015, 33(17): 1881-1888. DOI: 10.1200/JCO.2014.59.0539. ［9］ Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib［J］. J Clin Oncol, 2011, 29(15): e443-e445. DOI: 10.1200/JCO.2010.34.1313. ［10］ Chun SG, Choe KS, Iyengar P, et al. Isolated central nervous system progression on Crizotinib: an Achilles heel of nonsmall cell lung cancer with EML4ALK translocation?［J］. Cancer Biol Ther, 2012, 13(14): 1376-1383. DOI: 10.4161/cbt.22255. ［11］ Metro G, Lunardi G, Floridi P, et al. CSF concentration of crizotinib in two ALKpositive nonsmallcell lung cancer patients with CNS metastases deriving clinical benefit from treatment［J］. J Thorac Oncol, 2015, 10(5): e26-e27. DOI: 10.1097/JTO.0000000000000468. ［12］ Sakamoto H, Tsukaguchi T, Hiroshima S, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant［J］. Cancer Cell, 2011, 19(5): 679-690. DOI: 10.1016/j.ccr.2011.04.004. ［13］ Kodama T, Tsukaguchi T, Yoshida M, et al. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance［J］. Cancer Lett, 2014, 351(2): 215-221. DOI: 10.1016/j.canlet.2014.05.020. ［14］ Kodama T, Hasegawa M, Takanashi K, et al. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases［J］. Cancer Chemother Pharmacol, 2014, 74(5): 1023-1028. DOI: 10.1007/s0028001425786. ［15］ Nanjo S, Nakagawa T, Takeuchi S, et al. In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4ALK lung cancer cell line. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases［J］. Cancer Sci, 2015, 106(3): 244-252. ［16］ Bartels AL, Kortekaas R, Bart J, et al. Bloodbrain barrier Pglycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration［J］. Neurobiol Aging, 2009, 30(11): 1818-1824. DOI: 10.1016/j.neurobiolaging.2008.02.002. ［17］ Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinibresistant ALKrearranged nonsmallcell lung cancer (AF002JG): results from the dosefinding portion of a phase 1/2 study［J］. Lancet Oncol, 2014, 15(10): 1119-1128. DOI: 10.1016/S14702045(14)703626. ［18］ Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALKrearranged advanced nonsmallcell lung cancer (AF001JP study): a singlearm, openlabel, phase 12 study［J］. Lancet Oncol, 2013, 14(7): 590-598. DOI: 10.1016/S14702045(13)701426. ［19］ Seto T, Hida T, Nakagawa K, et al. Antitumor activity of alectinib in crizotinib pretreated ALKrearranged NSCLC in JP28927 study［J］. Annals of Oncol, 2014, 25(4): 426-470. ［20］ Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in nonsmall cell lung cancer［J］. Cancer Discov, 2014, 4(6): 662-673. DOI: 10.1158/21598290.CD130846. ［21］ Shaw A, Mehra R, Tan D, et al. Evaluation of ceritinibtreated patients with anaplastic lymphoma kinase rearranged (ALK+) nonsmall cell lung cancer (NSCLC) and brain metastases in the ASCEND1 study［J］. Annals of Oncol, 2014, 2(4): 426-470. ［22］ Mok T, Spigel D, Felip E, et al. ASCEND2: a singlearm, openlabel, multicenter phase 2 study of ceritinib in adult patients (pts) with ALKrearranged (ALK+) nonsmall cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ)［J］. J Clin Oncol, 2015, 33(Suppl): abstr 8059. ［23］ Felip E, Orlov S, Park K, et al. ASCEND3: a singlearm, openlabel, multicenter phase Ⅱ study of ceritinib in ALKinave adult patients (pts) with ALKrearranged (ALK+) nonsmall cell lung cancer (NSCLC)［J］. J Clin Oncol, 2015, 33(Suppl): abstr 8060. ［24］ Shaw AT, Mehra R, Tan D, et al. Ceritinib (LDK378) for treatment of patients with ALKrearranged (ALK+) nonsmall cell lung cancer (NSCLC) and brain metastases (BM) in the ASCEND1 tria［J］.Neuro Oncol, 2014, 16 (suppl 5): 39. ［25］ Awad MM, Shaw AT. ALK inhibitors in nonsmall cell lung cancer: crizotinib and beyond［J］. Clin Adv Hematol Oncol, 2014, 12(7): 429-439. ［26］ Camidge DR, Bazhenova L, Salgia R, et al. Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ nonsmall cell lung cancer (NSCLC)［J］. Clin Oncol, 2015, 33(supple): abstr 8062. ［27］ Zou HY, Friboulet L, Kodack DP, et al. PF06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models［J］. Cancer Cell, 2015, 28(1): 70-81. DOI: 10.1016/j.ccell.2015.05.010. ［28］ Felip E, Bauer T, Solomon B, et al. Safety and efficacy of lorlatinib (PF06463922) in patients with advanced ALK+ or ROS1+ nonsmallcell lung cancer (NSCLC)［J］. J Thorac Oncol, 2017, 12(1): S383-S384. DOI: 10.1016/j.jtho.2016.11.433.

[1]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[3]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[4]	Zhang Lu, Jiang Hua, Lin Zhou, Ma Chenying, Xu Xiaoting, Wang Lili, Zhou Juying. Analysis of curative effect and prognosis of immune checkpoint inhibitor in the treatment of recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2023, 50(8): 475-483.
[5]	Yang Lirong, Wang Yufeng. Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer [J]. Journal of International Oncology, 2023, 50(4): 220-226.
[6]	Ma Peihan, Zhang Lingming, Lu Ning, Zhang Mingxin. Effect of anesthesia on the recurrence and metastasis of hepatocellular carcinoma [J]. Journal of International Oncology, 2023, 50(2): 117-121.
[7]	Zhao Jianhao, Duan Yanchao. Research progress in the pathogenesis of extramedullary disease in multiple myeloma [J]. Journal of International Oncology, 2023, 50(1): 55-59.
[8]	Zhang Lu, Zhou Juying, Ma Chenying, Lin Zhou. Advances in immunotherapy for recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2022, 49(9): 517-520.
[9]	Peng Chen, Xie Yintong, Zhang Xin, Xie Peng. Research progress of maintenance therapy for cervical cancer [J]. Journal of International Oncology, 2022, 49(7): 430-435.
[10]	Wang Bin, Zhou Jiangyun, Liu Xi. Analysis of the clinical value of different radiotherapy schemes in patients with advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2021, 48(8): 484-488.
[11]	Chi Xiuying, Wang Hongbiao, Li Zhifeng, Lin Yingcheng. Progression in the therapies of relapse or metastatic esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2021, 48(12): 755-759.
[12]	Dai Ang, Sun Qing. CRYAB and tumors [J]. Journal of International Oncology, 2020, 47(6): 351-354.
[13]	Yang Chao, Wang Jianbo, Zhang Juhong, Wang Jialong. Overexpression of miR-125 inhibits proliferation and invasion of nasopharyngeal carcinoma cells by down-regulating FGF-2 [J]. Journal of International Oncology, 2020, 47(5): 257-263.
[14]	Zhang Yanqiang, Zhang Yang, Li Chunhua, Zhang Dianping, Liu Baoguo, Peng Xiangeng. High mobility group protein B1 and breast cancer [J]. Journal of International Oncology, 2020, 47(5): 297-300.
[15]	Li Kaichun, Wang Yajie. Current status of clinical researches on metastatic triple negative breast cancer [J]. Journal of International Oncology, 2020, 47(3): 169-173.